AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

AbbVie (NYSE: ABBV) has commenced construction of a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois.

Rhea-AI Summary

AbbVie (NYSE: ABBV) has commenced construction of a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. The $195 million investment is part of AbbVie's broader $10 billion capital investment plan over the next decade to enhance U.S. manufacturing capabilities.

The facility, expected to be fully operational by 2027, will focus on producing API components for immunology, oncology, and neuroscience medicines. This strategic move will relocate select API production from Europe and Asia to the U.S. The project will create new jobs, adding to AbbVie's existing workforce of 28,000 U.S. employees across all 50 states and Puerto Rico, including 6,000 jobs at 11 manufacturing sites.

Positive

• Significant $195 million investment in U.S. manufacturing expansion
• Part of larger $10 billion capital investment plan over next decade
• Strategic relocation of API production from Europe/Asia to U.S.
• Creation of new manufacturing jobs in Illinois
• Expansion of capabilities in immunology, oncology, and neuroscience medicine production

Negative

• Facility won't be operational until 2027, indicating a long implementation timeline

Argus Sep 29 session

+1.16% close to close Open Argus

Details

News Market Reaction – ABBV

On Sep 29, the day this news came out, ABBV closed 1.16% above the previous close.

Data tracked by StockTitan Argus for the Sep 29 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines
• Facility expected to be fully operational and serving patients by 2027
• Milestone marks progress on  AbbVie's long-term commitment to U.S. manufacturing

NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.

"Today's groundbreaking is an important milestone in AbbVie's ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the U.S.," said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. "Over the next decade, AbbVie plans to invest more than $10 billion in capital to add multiple new U.S. manufacturing plants and improve the lives of millions of patients in the U.S. and worldwide who depend on our medicines."

Active pharmaceutical ingredient manufacturing is a complex and multistep process that involves producing the active components responsible for medications' therapeutic effects. When completed, AbbVie's new North Chicago API facility will expand its chemical synthesis capabilities and enable AbbVie to bring API production for select products from Europe and Asia to the US to support domestic production of current and next generation neuroscience, immunology and oncology medicines.

With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 employees in the U.S. The previously announced $195 million investment in North Chicago will create new jobs and expand AbbVie's existing U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites. This investment also furthers AbbVie's long-term commitment to Illinois, where it is headquartered and includes more than 11,000 employees who work to develop and manufacture innovative medicines for patients worldwide.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.

Media:	Investors:
Gabby Tarbert	Liz Shea
(224) 244-0111	(847) 935-2211
gabrielle.tarbert@abbvie.com	liz.shea@abbvie.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-breaks-ground-on-new-north-chicago-active-pharmaceutical-ingredient-manufacturing-facility-302569711.html

SOURCE AbbVie

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is AbbVie investing in the new North Chicago API manufacturing facility?

AbbVie is investing $195 million in the new North Chicago API manufacturing facility.

When will AbbVie's new North Chicago manufacturing facility be operational?

The new facility is expected to be fully operational and serving patients by 2027.

How many U.S. manufacturing jobs does AbbVie currently support?

AbbVie currently supports more than 6,000 American jobs across 11 manufacturing sites in the United States.

What is AbbVie's total planned U.S. manufacturing investment over the next decade?

AbbVie plans to invest more than $10 billion in capital over the next decade to add multiple new U.S. manufacturing plants.

What types of medicines will be manufactured at AbbVie's new North Chicago facility?

The facility will manufacture active pharmaceutical ingredients (API) for immunology, oncology, and neuroscience medicines.